engineered erythrocytes (or red blood cells) covalently conjugated with commercially available anti-pd-1 antibodies on their membranes
Cell therapyexperimental
Clinical trial activity
1 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Jul 31, 2024 (NCT06528249)
Timeline
2020s
- Jan 1, 2024
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Programmed cell death 1 ligand 1INHIBITOR
CD274 inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06528249 | Phase 1 | Jul 31, 2024 | Government of China, Zhejiang University |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Government of China | Government | 1 | 0 | 1 | 2024 |
| Zhejiang University | Academic/Hospital | 1 | 1 | 1 | 2024 |
2 organizations
Page 1 / 1